INMED and Mentari Therapeutics are pursuing a definitive all-stock merger agreement, trading on the electronic stock exchange, and filing S-4 registration statements.
2 reports, 1 independent
Updated Sep 9
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
INMED and Mentari Therapeutics are pursuing a definitive all-stock merger agreement, trading on the electronic stock exchange, and filing S-4 registration statements.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Fulcrum Therapeutics and Slate Medicines announced a merger to advance next-generation therapeutics and will list on Nasdaq.
- A merger/combination involving XTEND and JFB Construction Holdings was planned, requiring SEC declaration of effectiveness and listing on Nasdaq and NYSE.
- OpenWorld and VerifyMe are merging, with the future combined entity aiming for a listing on the Nasdaq platform.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- Rapid Micro Biosystems is trading on the electronic stock exchange and is expanding its commercial sales pipeline.